ArticleJournal of nanobiotechnology2026
Human umbilical cord-derived mesenchymal stem cell exosomes ameliorate hepatocyte ferroptosis and sepsis-associated liver injury by restoring iron homeostasis in hepatocytes.
Article in Journal of nanobiotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Research Progress on Mesenchymal Stem Cells-Derived Small Size Vesicles for the Treatment of Liver Diseases.International journal of nanomedicine · 2026Review
Corrections and comments
- Erratum issued
Authors and funding
8 authors.
Funding
Abstract
Mesenchymal stem cells-derived exosomes (MSCs-Exo) constitute critical mediators of intercellular communication between stem cells and other cell types. Among these, exosomes derived from human umbilical cord mesenchymal stem cells (HUMSCs-Exo) have attracted considerable attention owing to their potent immunomodulatory capacity, low surface antigenicity, and favorable biosafety profile. Accumulating evidence indicates that HUMSCs-Exo can attenuate ferroptosis in target tissues across a spectrum of pathological conditions, including inflammatory bowel disease and viral cardiomyopathy, thereby mitigating tissue injury, improving organ function, and prolonging host survival. Nevertheless, the regulatory effects of HUMSCs-Exo on sepsis-associated liver injury (SALI) and hepatocellular ferroptosis, as well as the underlying molecular mechanisms, remain largely undefined. In this study, we identified pronounced differential gene expressions between control and septic mice hepatocytes, particularly within pathways related to iron metabolism, lipid metabolism, and ferroptosis. Building on these findings, we systematically characterized the dynamic progression of hepatocyte ferroptosis in septic mice through integrated in vivo and in vitro experiments, demonstrating a strong positive correlation between ferroptotic activity and the severity of liver injury. Using wild-type male C57BL/6J mice and the murine normal hepatocyte cell line NCTC1469, we further demonstrated that HUMSCs-Exo markedly upregulate the expression of FPN, xCT, GPX4, and FTH1 while concomitantly downregulating ACSL4 and TFRC. These molecular alterations reduced intracellular lipid peroxidation and labile iron accumulation, thereby robustly attenuating sepsis-induced hepatocyte ferroptosis and conferring significant hepatoprotective effects. Finally, these findings were validated in the immortalized human normal hepatocyte cell line THLE-2, in which HUMSCs-Exo similarly suppressed lipopolysaccharide-induced ferroptosis and cellular injury by modulating intracellular lipid peroxide and free iron levels. Collectively, our results demonstrate that HUMSCs-Exo exert potent inhibitory effects on sepsis-induced hepatocyte ferroptosis and confer protection against liver injury, primarily through the restoration of intracellular iron homeostasis and the suppression of lipid peroxidation. This study provides a novel therapeutic strategy for the treatment of SALI and ferroptosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.